false
0001728328
A1
BC
0001728328
2024-02-08
2024-02-08
0001728328
dei:FormerAddressMember
2024-02-08
2024-02-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 8, 2024
INMED
PHARMACEUTICALS INC.
(Exact
Name of Company as Specified in Charter)
British
Columbia |
|
001-39685 |
|
98-1428279 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
InMed
Pharmaceuticals Inc.
Suite
310 - 815 W. Hastings Street,
Vancouver,
B.C.
Canada |
|
V6C
1B4 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Company’s
telephone number, including area code: (604) 669-7207
Not
applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Shares, no par
value |
|
INM |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 |
Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Appointment
of Ms. N. Netta “Neeta” Jagpal as Chief Financial Officer and Corporate Secretary
On
February 8, 2024, the Board of Directors (the “Board”) of InMed Pharmaceuticals Inc. (the “Company”)
appointed Ms. N. Netta “Neeta” Jagpal (“Ms. Jagpal”) (aged 51) to serve, effective as of February
20, 2024 (the “Effective Date”), as Chief Financial Officer and Corporate Secretary of the Company. In her role as
Chief Financial Officer and Corporate Secretary, Ms. Jagpal shall formally assume the duties of the Company's principal financial officer
and principal accounting officer immediately following the Effective Date.
The
Company and Ms. Jagpal have entered into an employment agreement (the “Employment Agreement”), effective as of the
Effective Date, to memorialize her employment with the Company. Pursuant to the terms of the Employment Agreement, Ms. Jagpal will serve
as Chief Financial Officer and Corporate Secretary as and from the Effective Date and will continue until terminated as provided for
in the Employment Agreement. In consideration of the Services (as defined in the Employment Agreement) to be provided by Ms. Jagpal,
she will receive an annual base salary of CAD$325,000 and be eligible for an annual discretionary bonus, which will be subject to the
approval of the Board and the compensation committee of the Company, in their sole discretion, on an annual basis in accordance with
the Company’s annual performance and compensation review process, including consideration of the Company’s market capitalization
and financial stability. In accordance with the terms of the Employment Agreement, the target annual discretionary bonus for Ms. Jagpal
shall equal 40% of the base salary paid to Ms. Jagpal in the preceding 12-month period. Furthermore, pursuant to the terms of the Employment
Agreement, the Company may from time to time, in its sole discretion, grant to Ms. Jagpal stock options in the capital of the Company
(the “Options”) pursuant to the Company’s 2017 Amended and Restated Stock Option Plan (the “SOP”),
on the terms and conditions for such participation as established and changed from time to time by the Company in its sole discretion.
As contemplated by the Employment Agreement, and subject to necessary corporate approvals, Ms. Jagpal shall receive 50,000 Options, to
be granted at the earliest time allowable under the SOP and any of the Company’s blackout provisions.
The
foregoing description of the Employment Agreement is not complete and is qualified in its entirety by reference to the complete agreement,
which is attached hereto as Exhibit 10.1 and incorporated herein by reference. The foregoing description of the SOP is not complete and
is qualified in its entirety by reference to the complete SOP, a copy of which was included as Exhibit 4.2 to the Company’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on March 5, 2021.
Other
than as disclosed in this Item 5.02, there are no (i) family relationships between Ms. Jagpal and any director or executive officer of
the Company, and the Company has not entered into any transactions with Ms. Jagpal that are reportable pursuant to Item 404(a) of Regulation
S-K, nor (ii) arrangements or understandings between Ms. Jagpal and any other persons pursuant to which she will be appointed as an executive
officer of the Company.
Mr.
Jonathan Tegge (“Mr. Tegge”) will remain in his current role of Interim Chief Financial Officer, principal financial
officer and principal accounting officer, including with respect to the filing of the Company’s Form 10-Q for the quarterly period
ending December 31, 2023, up to and immediately prior to the Effective Date. In connection with the appointment of Ms. Jagpal as Chief
Financial Officer and Corporate Secretary, Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on
February 8, 2024, to serve as the Company’s Interim Chief Financial Officer (and likewise, as the Company’s principal financial
officer and principal accounting officer) immediately preceding the Effective Date and upon Ms. Jagpal’s appointment as Chief Financial
Officer and Corporate Secretary.
Item 7.01 |
Regulation FD Disclosure. |
On
February 9, 2024, the Company issued a press release (the “Press Release”) announcing the appointment of Ms. Jagpal
as Chief Financial Officer and Corporate Secretary of the Company. A copy of the Press Release is furnished herewith as Exhibit 99.1
and incorporated by reference herein.
The
information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by
reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such a filing.
Item 9.01. | Financial Statements and Exhibits. |
(d)
Exhibits:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INMED PHARMACEUTICALS INC. |
|
|
Date: February 9, 2024 |
By: |
/s/
Eric A. Adams |
|
|
Eric
A. Adams
|
|
|
President
& CEO |
3
Exhibit 10.1
EXECUTIVE
EMPLOYMENT AGREEMENT
THIS
AGREEMENT made this 20th day of February, 2024 (the “Effective Date”)
BETWEEN:
INMED
PHARMACEUTICALS INC., a company incorporated under the laws of British Columbia with offices at Suite 310, 815 West Hastings St.,
Vancouver, B.C., V6C 1B4 (the “Company”)
AND:
Narinder
Netta “Neeta” Jagpal (the “Executive”), of 14280 90A Ave., Surrey, BC V3V 7X9
(each
a “Party” and together, the “Parties”)
WHEREAS:
| A. | The
Company is a clinical stage pharmaceutical company that specializes in developing therapies
through the research and development of novel, cannabinoid-based and other pharmaceutical
therapies to treat disease combined with innovative drug delivery systems; |
| B. | The
Executive has the expertise, qualifications and required certifications to perform the services
contemplated by this Agreement; and |
| C. | The
Company and the Executive have agreed to set out in writing the terms and conditions of the
Executive’s continued employment. |
NOW
THEREFORE, in consideration of the mutual covenants and agreements contained in this Agreement and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
| (a) | Terms
of Employment. The Executive will be continue to be employed by, and will continue to
serve, the Company on the terms and conditions set out herein. |
| (b) | Position
and Services. The Executive will hold the position of Chief Financial Officer and Corporate
Secretary and will have powers and duties consistent with such position as may from time
to time be prescribed by the CEO and Board of Directors of the Company (the “Board”),
as outlined in Exhibit A (the “Services”). The Executive will report directly
to the CEO and will comply with all lawful instructions given by the CEO. |
| (c) | Term.
The terms and conditions of this Agreement will have effect as and from the Effective Date
and the Executive’s employment will continue until terminated as provided for in this
Agreement (the “Term”). |
| (d) | Policies.
The Executive’s employment with the Company is subject to and governed by the Company’s
policies as established and amended by the Company from time to time in its sole discretion.
Performance of Duties. The Executive will perform the Services in a competent and
efficient manner and on an exclusive, full-time basis. The Employee’s principal place
of employment initially will be at InMed’s offices and, with the consent of the CEO,
will be allowed to work from their home in Canada, although the Employee understands and
agrees that they may be required to travel to the U.S. or other locations for the purposes
of meetings, conferences, business development or other reasons related to their employment
for business reasons. |
| (e) | The
Executive may manage their personal investments or engage in charitable or other community
activities as long as those services and activities do not interfere with the Executive’s
performance of his duties to the Company. The Executive will at all times act in good faith
to the Company. |
The
Executive may participate in business associations, charitable organizations or other similar organizations, subject to the reasonable
objection of the Company and provided that it does not interfere with the proper discharge of the Executive’s duties to the Company.
However, while employed by the Company, the Executive must not carry out any other work or be involved in any other business for the
Executive or any other person, firm or company (whether for compensation or not,) without first obtaining written permission from the
Company. The Executive represents that they are not currently involved with any other business for which they must seek such permission.
| (f) | Fiduciary.
The Executive acknowledges that the Executive will be in a fiduciary relationship with the
Company and will continue to owe fiduciary obligations to the Company. The provisions of
this Agreement including the Exhibits are additional to and do not amend, replace or otherwise
reduce the Executive’s fiduciary obligations at law or equity. |
| (g) | Compliance
with the Law. The Executive will work with the Company, including Counsel, to ensure
that the Company is at all times in compliance with applicable laws, including without limitation
the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), the
Corruption of Foreign Public Officials Act (Canada), the Foreign Corrupt Practices
Act (U.S.) and all SEC and BCSC rules and regulations for a reporting company. |
| 2 | REMUNERATION
AND BENEFITS |
| (i) | The
Company will pay the Executive an annual salary of C$325,000, for full-time performance of
the Services (the “Base Salary”). The Base Salary is payable in a manner
that is consistent with the Company’s usual payroll practices for senior executives
as amended from time to time. Currently, this practice involves the base salary being paid
semi-monthly in arrears, in equal instalments and shall be subject to such deductions of
tax and other applicable contributions as is required by law in Canada, as applicable. |
| (ii) | The
Executive’s Base Salary will be reviewed annually by the Board and the compensation
committee of the Company in accordance with the Company’s annual performance and compensation
review process, including consideration of the Company’s market capitalization and
financial stability. Any increase in Base Salary is at the sole discretion of the Company.
An increase in the Base Salary in any year or any number of years does not entitle the Executive
to any increase in the Base Salary in any subsequent year. |
| (iii) | The
Company may decrease the Base Salary, but only in the case of an across-the-board salary
reduction affecting all senior executives of the Company and with any such reduction being
of similar magnitudes across all executives. The Company will not decrease the Base Salary
of the Executive for at least six (6) months from the Effective Date. Should a salary reduction
be implemented across-the-board affecting all senior executives of the Company, then the
decrease will be in similar magnitude across all executives, and not exceed more than 10%
of the Executive’s base salary at the time the salary reduction is effected. Any such
reduction shall not constitute a constructive dismissal of the employment of the Executive
by the Company. |
| (b) | Bonus.
The Executive is eligible to be considered for an annual discretionary bonus which will be
subject to the approval of the Board and the compensation committee of the Company, in their
sole discretion, on an annual basis in accordance with the Company’s annual performance
and compensation review process, including consideration of the Company’s market capitalization
and financial stability. Payment of a bonus in any one year or any number of years will not
entitle the Executive to any payment of a bonus in any subsequent year. The target annual
discretionary bonus for the Executive is equal to 40% of Base Salary paid to the Executive
in the preceding 12 month (fiscal year) period (the “Target Bonus”). |
| (c) | Signing
Bonus. The Company will pay the Executive a signing bonus in the amount of C$1,000, less
statutory deductions, in conjunction with the first pay period for which the Executive is
eligible. |
| (d) | Stock
Options. The Company may from time to time in its sole discretion grant to the Executive
stock options in the capital of the Company (the “Options”) pursuant to
the Company’s Incentive Stock Option Plan (the “SOP”) on the terms
and conditions for such participation as established and changed from time to time by the
Company in its sole discretion. For clarity, any Options that are granted will be granted
at the market price in accordance with and subject to the options policies of the applicable
exchange and will be subject to the Company’s Insider Trading Guidelines including
the blackout provisions therein. The terms and conditions relating to the Options will be
subject to the Option Agreement that is entered into as a condition of the grant of the Options.
If there is any conflict between the terms of this Agreement and the SOP, the terms of the
SOP will govern. If there is any conflict between the terms of this Agreement and the Option
Agreement, the terms of this Agreement will govern to the extent of the conflict. |
The
Executive will receive the following options, to be granted at the earliest time allowable under the SOP and any blackout provisions*:
Date
of Grant |
Number
of Options |
Price |
Expiry
Date |
TBD* |
50,000 |
TBD
on Date of Grant |
Five
years from Date of Grant |
| (e) | Expenses.
The Company will reimburse the Executive for all ordinary and necessary expenses incurred
by the Executive in performing services under this Agreement, including reasonable travel
and living expenses when Employee travels for business purposes to fulfill their duties.
Reimbursement or payment of such expenses will be made in accordance with the Company’s
policies and procedures provided in the Employee Handbook and as established by the Company
for its senior executives as amended by the Company from time to time in its sole discretion. |
The
Company also agrees to reimburse the Executive for:
| i. | up
to C$400 per month for parking (as per contract or receipts made available to the Company); |
| ii. | monthly
cell phone expense up to C$100 (as per contracts made available to the Company); |
| iii. | professional
fees such as Annual Chartered Professional Accountant dues and annual professional development
fees associated with maintaining standing in the Institute of Chartered Professional Accountant
and Governance Professionals of Canada; |
| (f) | Other
Benefits. The Company will facilitate the Executive’s enrolment in the Company’s
insured benefits plans as amended from time to time by the Company in its sole discretion
or by the Company’s insurance carrier. Eligibility to participate in the plans and
to receive benefits under the plans, and the payment of benefits will be subject to the terms
and requirements of the applicable insurance carrier in accordance with the formal benefits
plan documents and policies. The Company’s financial liability is limited to paying
its portion of the premium cost of the benefits. The Company will not be responsible for
the payment of benefits in any circumstance. The Company reserves the right, in its sole
discretion, to amend, change or terminate any of the insurance benefit plans or providers
in whole or in part at any time. |
| (g) | Vacation.
The Executive is entitled to paid holidays and vacation days each year, in an amount determined
in accordance with and subject to the Company’s applicable policies in effect, and
as may be amended from time to time. The Executive will be entitled to 25 days of vacation
per calendar year, which will be pro-rated for partial years of service, including for any
period in which the Executive is not a full-time employee. Vacation days will be scheduled
at times that are mutually acceptable to the Executive and the Company. Carry-over of vacation
days will be according to Company policy, and any accrued but unused vacation days will be
paid out upon termination or otherwise as per Company policies, as amended by the Company
from time to time in its sole discretion. |
| (a) | Competition.
During the Term, the Executive will not compete with the Company in any manner whatsoever. |
| (b) | Confidentiality
and Intellectual Property Agreement. The Executive and the Company will enter into a
Confidentiality and Assignment of Inventions Agreement in the form attached hereto as Exhibit
B. |
| (c) | Restrictive
Covenant Agreement. The Executive will execute and abide by the Restrictive Covenant
Agreement attached hereto as Exhibit C. |
| (d) | Acknowledgement.
The Executive acknowledges that the consideration provided by the Company under this Agreement
is in part in exchange for the Executive’s agreement to execute and abide by the Exhibits
B and C to this Agreement, and that the Executive has received sufficient consideration for
the Executive’s agreement to execute and abide by those Exhibits. |
| (a) | Definitions.
In this Agreement, |
| (i) | “Change
in Control” means the consummation of any of the following: |
| (A) | the
sale of all or substantially all of the assets of the Company to an unrelated person or entity, |
| (B) | a
merger, reorganization, or consolidation involving the Company in which the shares of voting
stock outstanding immediately prior to the transaction represent or are converted into or
exchanged for securities of the surviving or resulting entity that, immediately upon completion
of the transaction, represent less than 51% of the outstanding voting power of the surviving
or resulting entity, |
| (C) | the
acquisition of all or a majority of the outstanding voting stock of the Company in a single
transaction or a series of related transactions by a person or group of persons, or |
| (D) | any
other acquisition of the business of the Company, as determined by the Board, |
but
any public offering by the Company, or another capital raising event, or a merger effected solely to change the Company’s domicile
does not constitute a Change in Control;
| (ii) | “Date
of Termination” means: |
| (A) | if
the Executive’s employment is terminated by their death, the date of death; |
| (B) | if
the Executive’s employment is terminated by the Company for any reason, on the effective
date of the Notice of Termination that is given to the Executive; |
| (C) | if
the Executive terminates their employment under section 6, Resignation Without Good Reason,
on the effective date of resignation specified by the Executive in the Notice of Termination
subject to the Company’s rights pursuant to section 6; or |
| (D) | if
the Executive resigns from their employment under section 7 for Good Reason following a Change
in Control of the Company, the date on which the Executive provides the Company with the
Notice of Termination. |
| (iii) | “Disability”
means the inability of the Executive to substantially perform the Services on a full-time
basis for a continuous or cumulative period of six months in any 18-month period where such
inability is a result of physical or mental illness or injury and where it would cause undue
hardship to the Company to accommodate. |
| (iv) | “Good
Reason” means the occurrence of any of the following events without the Executive's
prior written consent: |
| (A) | a
change in the Executive’s position which materially reduces the Executive’s responsibilities
from the responsibilities in effect immediately prior to the Change of Control, |
| (B) | a
reduction by the Company of the Base Salary or Target Bonus percentage other than as specifically
permitted in accordance with section 2(a)(iii) of this Agreement, or |
| (C) | a
relocation of Executive’s principal place of employment by more than 30 kilometers; |
| (A) | the
Executive is convicted of a crime involving dishonesty, breach of trust, or physical harm
to any person (excluding driving while affected by drugs or alcohol) or any violation of
provincial or federal securities laws, |
| (B) | the
Executive willfully engages in conduct that is in bad faith and/or materially injurious to
the Company, monetarily, reputationally, or otherwise, including but not limited to, misappropriation
of trade secrets, fraud, embezzlement or moral turpitude, |
| (C) | the
Executive commits a material breach of this Agreement including the Exhibits, |
| (D) | the
Executive willfully and on a continuing basis refuses to implement or follow a material lawful
policy or reasonable directive of the Company, or |
| (E) | the
Executive willfully and on a continuing basis fails to perform his duties hereunder diligently
and professionally; or |
| (F) | the
Executive engages in any other conduct that constitutes just cause to terminate the employment
relationship at common law; and |
| (vi) | “Notice
of Termination” means a written notice by the Company or the Executive that provides
the other Party with notice of termination of the employment under this Agreement and indicates
the specific termination provision in this Agreement upon which the termination is based. |
| (b) | Termination.
The Executive’s employment with the Company may be terminated as follows: |
| (i) | by
the Company for Just Cause; |
| (ii) | by
the Company in its sole discretion without Just Cause subject to providing the payments and
entitlements set out in section 5 of this Agreement except as provided in section 7; |
| (iii) | by
the Executive as provided for in section 6 or 7 of this Agreement; |
| (iv) | by
the Company following a Change in Control as provided for in section 7 of this Agreement; |
| (v) | by
the Company following receipt of a Notice of Termination by the Executive as contemplated
in section 6 of this Agreement; |
| (vi) | by
the Executive’s death, in which case a Notice of Termination will be deemed to have
been given by the Executive to the Company as of the Date of Termination; or |
| (vii) | by
the Company as a result of Disability, but nothing in this section 4(b)(vii) will reduce
the Executive’s rights, if any, under the Company’s insurance benefits plans
accruing prior to termination or under applicable law, |
and
the Company shall pay or provide to the Executive (or the authorized representative or estate of the Executive if applicable) any earned
but unpaid Base Salary, unpaid expense reimbursements validly incurred by the Executive, accrued but unused vacation subject to Company
policy, any vested benefits the Executive may have under any employee benefit plan of the Company, and any earned but unpaid annual bonus
for the prior fiscal year, that is due and owing for Services provided up to and including the Date of Termination (collectively the
“Accrued Benefits”). If the termination is initiated by the Company, the Company will also provide the notice of termination
or wages in lieu of notice owing pursuant to the minimum requirements of the B.C. Employment Standards Act (the “ESA
Entitlement”).
| (c) | Return
of Materials. The Executive will return to the Company all Company documents, files,
manuals, books, software, equipment, keys, identification or credit cards, and all other
property belonging to Company, including electronic devices and any necessary passwords and
encryption codes immediately upon the termination of the Executive’s employment with
the Company for any reason. |
| (d) | Resignation
as Officer and/or Director: In the event of termination of the employment of the Executive
for any reason, the Executive will, as of the Termination Date, resign as an officer, secretary
and/or director of the Company and any other entity of which the Executive is an officer,
secretary or director at the request of Company or otherwise as part of the Services. |
| (e) | Release.
In order to receive the entitlements set out in this Agreement that are in excess of the
ESA Entitlement, the Executive, or the estate of the Executive as applicable, will be required,
within 14 days of the Date of Termination, to sign and return a Release in the form attached
as Exhibit D to this Agreement (the “Release”) failing which the Executive
will only be entitled to the ESA Entitlement, if any. For clarity, if the Executive does
not sign and return the Release to the Company, then the Executive will still be bound by
the provisions of this Agreement, including each of the obligations set out in the Exhibit
B and C. |
| (f) | Full
Satisfaction. The amounts payable to the Executive pursuant to the express terms of this
Agreement, if any, constitute full and final satisfaction of the Executive’s rights
and entitlements in connection with the termination of the Executive’s employment,
including without limitation pursuant to the B.C. Employment Standards Act (“ESA”)
and the common law, and the Company shall have no further obligation or liability of any
kind for any claim, action, complaint, or demand whatsoever, whether at law or equity, under
contract, or under any legislation from time to time applicable and in force or otherwise,
for any remedy, damages, or loss sustained or sought by the Executive arising out of the
employment of the Executive by the Company or the termination of that Employment. |
| 5 | TERMINATION
WITHOUT JUST CAUSE |
If
the Executive’s employment is terminated by the Company without Just Cause pursuant to section 4(b)(ii), then in addition to the
ESA Entitlement and the payment of any Accrued Benefits, and subject to the Executive first providing the Company with an executed Release
pursuant to section 4(e), the Company shall pay the Executive an amount (the “Severance Amount”) calculated as follows:
| (a) | If
terminated any time during the initial twelve (12) months from the Effective Date of Employment,
an amount equal to six (6) months’ Base Salary, less an amount equal to the ESA Entitlement
provided by the Company to the Executive; |
| (b) | If
terminated any time after the initial twelve (12) months from the Effective Date of Employment,
an amount equal 12 months’ (12) months’ Base Salary plus one month per year of
employment completed beyond 12 month anniversary of the Effective Date of Employment, up
to a maximum of eighteen (18) months total, less an amount equal to the ESA Entitlement provided
by the Company to the Executive; |
| (c) | in
addition to the amount payable under section 5 (a) or (b), a bonus payment equal to the average
of the actual annual bonus payments, if any, made to the Executive from the previous 3 calendar
years preceding the Date of Termination, pro-rated for the then current calendar year up
to and including the Date of Termination. |
The
Company shall pay the Severance Amount within 5 business days after the date that the Company receives the signed Release as per section
4(e) of this Agreement, provided that the Company, in its sole discretion, may pay the Severance Amount by way of one or more lump sum
payments, by way of salary continuance or by a combination of both.
For
clarity, if the Executive does not provide the Company with an executed Release on the timelines set out above, the Executive will not
be entitled to receive the Severance Amount.
| 6 | RESIGNATION
WITHOUT GOOD REASON |
The
Executive may terminate their employment by providing to the Company Notice of Termination of their employment at least 90 days prior
to the effective date of resignation. During such notice period, the Executive shall continue to diligently perform all of the Executive’s
duties. Upon receipt of a Notice of Termination from the Executive pursuant to this section 6, the Company may, at its option:
| (a) | direct
that the Executive cease providing part or all of the Services and such direction will not
constitute an express or constructive termination of the employment of the Executive by the
Company, provided that the Company will remain bound to pay the Base Salary for the balance
of the notice period provided by the Executive; or |
| (b) | terminate
the employment of the Executive at any time within the notice period, including where the
Company first elects to proceed with the option under section 6 (a) above, in which case,
unless the termination is for Just Cause, the Company will pay the Executive only the lesser
of either (i) an amount equal to the Base Salary from the date the Executive provided the
Notice of Termination until the earlier of the date of resignation or retirement selected
by the Executive and 90 days from the date the Executive provided the Notice of Termination,
and (ii) the ESA Entitlement. |
For
clarity, if the Company elects to terminate the employment of the Executive after receiving Notice of Termination from the Executive,
the Company will not owe the Executive the Severance Amount and all benefits coverage will cease as of the Date of Termination set out
in the Employer’s Notice of Termination.
If
within 12 months following the effective date of a Change in Control,
| (a) | the
Company terminates the Executive’s employment without Just Cause; or |
| (b) | the
Executive resigns from their employment with the Company for Good Reason, effective immediately,
by providing the Company with a Notice of Termination specifying the basis for this resignation, |
then,
| (c) | in
addition to the ESA Entitlement and payment of the Accrued Benefits, and in lieu of paying
the Executive the Severance Amount pursuant to section 5 (if applicable), subject to the
Executive first providing the Company with an executed Release pursuant to section 4(e),
the Company shall pay to the Executive an amount (the “Change in Control Severance
Amount”) as follows: |
| (i) | an
amount equal to the greater of entitlement set out in section 5 and 12 months’ Base
Salary less an amount equal to the ESA Entitlement provided by the Company to the Executive;
plus |
| (ii) | an
amount equal to the average of the actual annual bonus payments, if any, made to the Executive
from the previous 3 calendar years preceding the Date of Termination, pro-rated for the then
current calendar year up to and including the Date of Termination. |
The
Company shall pay the Change in Control Severance Amount within 5 business days of the date that the Company receives the signed Release
as per section 4(e) of this Agreement, provided that the Company, in its sole discretion, may pay the Change in Control Severance Amount
by way of one or more lump sum payments, by way of salary continuance or by a combination of both; and
| (d) | notwithstanding
anything to the contrary in any applicable Option Agreement or stock-based award agreement,
all Options and other stock-based awards held by the Executive shall immediately accelerate,
vest, and become fully exercisable or non-forfeitable as of the Date of Termination under
this section 7. |
| 8 | Stock
Option Plan (SOP) Entitlements |
| (a) | On
a termination of the employment of the Executive for any reason and whether initiated by
the Company or the Executive, the rights of the Executive with respect to any Option will
be determined in accordance with the SOP and the applicable Option Agreement. |
| (b) | Acknowledgement:
The Executive acknowledges and agrees that the provisions of this Agreement and the SOP
may significantly limit and restrict the Executive’s common law rights and entitlements
to remuneration upon the termination of the Executive’s employment for any reason,
whether the termination is voluntary or involuntary, and whether the termination was initiated
by the Executive, by the Company, or otherwise, and that the Executive has had a reasonable
opportunity to review these provisions and seek legal advice. |
Initial
Here: NJ
| (a) | Withholdings
and Currency. All payments made by the Company to the Executive under this Agreement
will be in Canadian dollars and subject to tax or other amounts required to be withheld by
the Company under applicable law. Nothing in this Agreement is to be construed to obligate
the Company to design or implement any compensation arrangement in a way that minimizes tax
consequences for the Executive. |
| (b) | Remedies.
The Executive acknowledges that damages cannot be an adequate remedy to compensate the Company
for any actual or anticipatory breach by the Executive of section 1(e) of this Agreement
or Exhibits B and C. In the event of a breach or anticipatory breach by the Executive of
the provisions of section 1(e) of this Agreement or the Exhibits B and C, the Company will
be entitled to interim, interlocutory and permanent injunctions restraining the Executive
from such breach. Nothing contained herein will be construed as prohibiting the Company from
pursuing any other remedies available at law or equity for such breach or anticipatory breach
of this Agreement including the Exhibits nor limiting the amount of damages recoverable in
the event of a breach or anticipatory breach by the Executive of the provisions of section
1(e) of this Agreement or the Exhibits B and C. Without limiting the generality of the foregoing,
the Executive acknowledges that, in the event of a breach or threatened breach by the Executive
of any of the provisions of section 1(e) of this Agreement or the Exhibits B and C, the damages
of the Company may exceed the amount paid to the Executive pursuant to this Agreement. If
the Executive breaches any provision of this Agreement, then despite any term or condition
to the contrary and without limitation to any remedy the Company may be entitled to, any
entitlement of the Executive to remuneration that has not yet been paid or provided is immediately
terminated except and only to the extent that the compensation is minimally owing under the
ESA or any other applicable legislation. |
| (c) | Assignment
and Benefit. The Executive will not assign or transfer this Agreement or any rights or
obligations hereunder. The Company may assign this Agreement to any successor to the Company
and in the event of such an assignment the provisions hereof will inure to the benefit of,
and be binding upon, each successor of the Company, whether the successor arises by merger,
consolidation or transfer of all or substantially all of its assets. This Agreement shall
inure to the benefit of and be enforceable by the Executive's successors and legal representatives. |
| (d) | Non-Waiver.
Failure on the part of either Party to complain of any act or failure to act of the other
of them or to declare the other Party in default of this Agreement, irrespective of how long
such failure continues, will not constitute a waiver by such Party of their rights hereunder
or of the right to then or subsequently declare a default. |
| (e) | Severability.
If any provision in this Agreement including the Exhibits is found to be invalid or unenforceable,
then to the greatest extent permitted by law the scope of any unenforceable provision will
be deemed modified and diminished by the Parties to the minimum extent necessary to render
such provision valid and enforceable, and in any event the invalidity or unenforceability
of any such provision will not affect the validity or enforceability of any other provision
of this Agreement including the Exhibits. |
| (f) | Entire
Agreement. This Agreement, including the Exhibits and any Option Agreements, constitutes
the entire agreement between the Parties with respect to the employment of the Executive
and supersedes any and all agreements, understandings, warranties or representations of any
kind, written or oral, express or implied, including any relating to the nature of the position
or its duration, and each of the Parties releases and forever discharges the other of and
from all manner of actions, causes of action, claim or demands whatsoever under or in respect
of any agreement. |
| (g) | Survival.
The provisions of sections 1(f) and 3 to 9 inclusive this Agreement and the Exhibits survive
the termination of this Agreement and/or the termination of the Executive’s employment
to the extent necessary to effectuate the intent of the Parties as expressed in this Agreement. |
| (h) | Modification
of Agreement. Any modification of this Agreement must be in writing and signed by both
the Company and the Executive or it will have no effect and will be void. |
| (i) | Headings
and Sub-Headings. Descriptive headings and sub-headings are for convenience only and
will not control or affect the meaning or construction of any provision of this Agreement. |
| (j) | Disputes.
All disputes arising out of or in connection with this Agreement and the employment relationship
between the Parties, including the Exhibits, are to be referred to and finally resolved by
a single arbitrator pursuant to the Domestic Commercial Rules of Procedure of British Columbia
administered by the Vancouver International Commercial Arbitration Centre (VanIAC) pursuant
to its applicable Rules. The place of arbitration will be Vancouver, British Columbia. |
Either
Party may apply to the arbitrator for injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.
Before an arbitrator is appointed or makes a final determination on the merits of the controversy, either Party also may, without waiving
any remedy under this Agreement, seek from any court of competent jurisdiction in British Columbia sitting in Vancouver any interim or
provisional relief that is necessary to protect the rights or property of that Party.
Any
decision of the Arbitrator shall be final on the Parties and their respective successors and assigns unless either party appeals such
decision to a three party arbitration panel within 30 days, whether on a question of law, a question of fact, or a mixed question of
law or fact.
Each
Party shall bear its own costs of any arbitration proceedings commenced pursuant to this Agreement, including legal and travel costs,
and the Parties shall equally share the fees of the Arbitrator and the facility fees.
The
Arbitration procedures, hearings, documents, and award shall remain strictly confidential between the Parties.
Acknowledgement:
The Executive acknowledges and agrees that the Executive has had a reasonable opportunity to review this arbitration provision, inquire
about the nature and extent of the costs of arbitration and seek legal advice.
Initial
Here: NJ
| (k) | Governing
Law and Language. This Agreement will be governed by and construed according to the laws
of the Province of British Columbia and the laws of Canada applicable therein. |
| (l) | Notices.
Any notices, requests, demands, and other communications provided for by this Agreement are
sufficient if in writing and delivered in person or sent by a nationally recognized overnight
courier service or by registered or certified mail, postage prepaid, return receipt requested,
to the Executive at the last address the Executive has filed in writing with the Company
or, in the case of the Company, at its main offices, attention to the Corporate Secretary. |
| (m) | Collection
and Use of Personal Information. The Executive acknowledges that the Company will collect,
use and disclose health and other personal information for employment and business related
purposes. The Executive consents to the Company collecting, using and disclosing health and
other personal information of the Executive for employment and business related purposes
in accordance with the privacy policy of the Company. |
| (n) | Minimum
Requirements. Nothing in the Agreement is intended to contract out of any minimal substantive
or procedural entitlements or rights that the Executive may have under the ESA, B.C. Human
Rights Code or any other applicable legislation. If any provision in the Agreement provides
the Executive with an entitlement that does not meet what the Executive is minimally entitled
to under the ESA, Human Rights Code or any other applicable legislation, then
the provision is deemed modified so that the Executive receives the minimum entitlement required
under the ESA, Human Rights Code or any other applicable legislation. |
| (o) | Independent
Legal Advice. The Executive agrees that the Executive has obtained or has had an opportunity
to obtain independent legal advice in connection with this Agreement, and further acknowledges
that the Executive has read, understands, and agrees to be bound by all of the terms and
conditions contained herein. The Executive further agrees that the consideration described
aforesaid is accepted voluntarily for the purpose of employment with the Company under the
terms and conditions described herein. |
| (p) | Use
of Discretion: Where this Agreement or Exhibits grant the Company a discretionary
power, the Company will be entitled to exercise that power in its sole and absolute discretion
for the best interests of the business of Company except that any discretion exercisable
with respect to the Restrictive Covenant Agreement must be exercised reasonably. |
| (q) | Counterparts.
This Agreement may be executed in any number of counterparts, and by each Party on separate
counterparts, each of which counterparts, when so executed and delivered is to be taken to
be an original; but those counterparts together constitute one and the same document. PDF,
facsimile, scanned, and electronic signatures have the same legal effect as original ink
signatures. |
IN
WITNESS WHEREOF, the Parties hereto have duly executed this Agreement, and the Executive has initialed where indicated above,
as of the day and year first written above.
/s/ Eric A. Admas |
|
/s/ Netta Jagpal |
|
Eric A. Adams |
|
Narinder Netta “Neeta” Jagpal |
|
President and CEO |
|
|
|
Exhibit
A – Services
Chief
Financial Officer and Corporate Secretary
The
Chief Financial Officer (CFO) provides both operational and programmatic support to the organization. The CFO supervises the finance
unit and is the chief financial spokesperson for the organization. The CFO reports directly to the President/Chief Executive Officer
(CEO) and directly assists the Executive Team on all strategic and tactical matters as they relate to budget management, cost benefit
analysis, forecasting needs and the securing of new funding.
ESSENTIAL DUTIES AND
RESPONSIBILITIES
| ● | As
a business partner to the CEO and senior leadership team, the CFO will assess organizational
performance against both the prior year results, the annual budget, and the company’s
long-term strategy. |
| ● | The
CFO role includes U.S. Securities and Exchange Commission designations for Principal Financial
Officer and Principal Accounting Officer under Rule 16a-1(f). |
| ● | Assist
in performing all tasks necessary to achieve the organization's mission and help execute
staff succession and growth plans. |
| ● | Train
staff on raising awareness and knowledge of financial management matters. |
| ● | Participate
in developing new business, specifically: assist the CEO in identifying new funding opportunities,
the drafting of prospective budgets, and determining cost effectiveness of prospective service
delivery. |
| ● | Assess
the benefits of all prospective contracts and advise the Executive Team on implementation
matters. |
| ● | Ensure
adequate controls are installed and that substantiating documentation is approved and available
such that all purchases may pass independent and governmental audits. |
| ● | Provide
the Executive Team with an operating budget. Work with the Executive Team to ensure programmatic
success through cost analysis support, and compliance with all contractual and programmatic
requirements. This includes: |
| ◦ | 1)
interpreting legislative rules and regulations to ensure compliance with all federal, state,
local and contractual guidelines, |
| ◦ | 2)
ensuring that all government regulations and requirements are disseminated to appropriate
personnel, and |
| ◦ | 3)
monitoring compliance. |
| ● | Oversee
the management and coordination of all fiscal reporting activities for the organization including:
organizational revenue/expense and balance sheet reports, reports to funding agencies, development
and monitoring of organizational and contract/grant budgets. |
| ● | Oversee
all purchasing and payroll activity for staff and participants. |
| ● | Develop
and maintain systems of internal controls to safeguard financial assets of the organization
and oversee federal awards and programs. |
| ● | Oversee
the coordination and activities of independent auditors and ensure that the preparation of
the quarterly and annual financial statements and MD&A is in accordance with all government
policies and provincial and federal and other required supplementary schedules and information. |
| ● | Attend
Board and Subcommittee meetings (as warranted), including being the lead staff on the Audit
and Risk Committee. Acts as secretary to the Board of Directors. |
| ● | Monitor
banking activities of the organization. |
| ● | Ensure
adequate cash flow to meet the organization's needs. |
| ● | Investigate
cost-effective benefit plans and other fringe benefits which the organization may offer employees
and potential employees with the goal of attracting and retaining qualified individuals. |
| ● | Oversee
the production of monthly reports including reconciliations with funders and pension plan
requirements, as well as financial statements and cash flow projections for use by Executive
management, as well as the Audit and Risk Committee and Board of Directors. |
| ● | Assist
in the design, implementation, and timely calculations of wage incentives, commissions, and
salaries for the staff. |
| ● | Oversee
Accounts Payable and Accounts Receivable and ensure a disaster recovery plan is in place. |
| ● | Oversee
business insurance plans. |
| ● | Oversee
the maintenance of the inventory of all fixed assets, including assets purchased with government
funds (computers, etc.) assuring all are in accordance with federal regulations. |
| ● | Other
projects as may be assigned from time-to-time by the CEO and Board of Directors. |
Exhibit
B – Confidentiality and Assignment of Inventions Agreement
Dated:
20 February 2024
WHEREAS:
| A. | In
accordance with the terms of the Executive Employment Agreement between the Executive and
the Company dated 20 February 2024 (the “EEA”), the Executive has agreed
to execute this Confidentiality and Assignment of Inventions Agreement on the terms set out
herein. |
NOW
THEREFORE for good and valuable consideration, including the consideration contemplated by the EEA, the receipt and sufficiency of which
is acknowledged by the Executive, the Executive and the Company agree as follows:
The
capitalized terms have the meanings ascribed to them in the EEA, and the following terms have the following meanings:
| (a) | “Affiliate”
means, in respect of the Company, a company or other entity which directly or indirectly
controls, is controlled by, or is under common control with, the Company. For the purposes
of this definition, “control” means direct or indirect beneficial ownership
of a greater than 50% interest in the income of such company or entity or such other relationship
as, in fact, constitutes actual control. |
| (b) | "Business"
or "Business of the Company" means: |
| (i) | researching,
developing, commercializing, producing and marketing novel, cannabinoid-based and other pharmaceutical
therapies to treat disease combined with innovative drug delivery systems; or |
| (ii) | any
other area in which the Company has an active research and development program on the date
the Executive's employment with the Company terminates and in connection with which the Executive
directly provided Services or had direct supervisory responsibilities. |
| (c) | “Confidential
Information” shall mean all information, knowledge, or data, whether in written,
oral, electronic or other form, relating to the Business of the Company, whether or not conceived,
originated, discovered or developed in whole or in part by the Executive, that is not generally
known to the public or to other persons who are not bound by obligations of confidentiality
and: |
| (i) | from
which the Company or its Affiliates derive economic value, actual or potential, from the
information not being generally known; or |
| (ii) | in
respect of which the Company or its Affiliates otherwise have a legitimate interest in maintaining
secrecy; |
and
which, without limiting the generality of the foregoing, shall include:
| (iii) | all
proprietary information licensed to, acquired, used or developed by the Company and its Affiliates
in its research and development activities (including but not restricted to the research
and development of cannabinoid-based and other pharmaceutical therapeutics and delivery technology),
other scientific strategies and concepts, designs, know-how, information, material, formulas,
processes, research data and proprietary rights in the nature of copyrights, patents, trademarks,
licenses and industrial designs; |
| (iv) | all
information relating to the Business of the Company, and to all other aspects of the structure,
personnel and operations of the Company and its Affiliates, including financial, clinical,
regulatory, marketing, advertising and commercial information and strategies, customer lists,
compilations, agreements and contractual records and correspondence; programs, devices, concepts,
inventions, designs, methods, processes, data, know-how, unique combinations of separate
items that is not generally known and items provided or disclosed to the Company or its Affiliates
by third parties subject to restrictions on use or disclosure; |
| (v) | all
know-how relating to the Business of the Company, including all biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and
quality control data and information, and all applications, registrations, licenses, authorizations,
approvals and correspondence submitted to regulatory authorities; |
| (vi) | all
information relating to the businesses of competitors of the Company or its Affiliates, including
information relating to competitors’ research and development, intellectual property,
operations, financial, clinical, regulatory, marketing, advertising and commercial strategies,
that is not generally known; |
| (vii) | all
information provided to the Company or its Affiliates by their agents, consultants, lawyers,
contractors, licensors or licensees and relating to the Business of the Company; and |
| (viii) | all
information relating to the Executive’s compensation and benefits, including salary,
vacation, stock options, perquisites, severance notice, rights on termination and all other
compensation and benefits, except that the Executive shall be entitled to disclose such information
to the Executive’s bankers, advisors, agents, consultants and other third parties who
have a duty of confidence to the Executive and who have a need to know such information in
order to provide advice, products or services to the Executive. |
All
Work Product shall be deemed to be the Company’s Confidential Information.
Notwithstanding
the foregoing, “Confidential Information” does not include information which the Executive can prove is information that
was in the public domain at the date of disclosure to the Executive, or thereafter entered the public domain through no fault of the
Executive (but only after it has entered the public domain) provided that any combination of information that is Confidential Information
will not be included within the exception merely because parts of the information were within the public domain unless the whole of the
combination itself was in the public domain.
| (d) | “Intellectual
Property” is used in its broadest sense and means and includes any statutory, common
law, equitable, contractual or proprietary rights or interests, recognized currently or in
future, in and to any Inventions, including, without limitation, rights and interests in
and to the following: |
| (i) | knowledge,
know-how and its embodiments, including trade secret information; |
| (ii) | patents
in inventions, and all applications therefor; |
| (iii) | copyrights
in artistic, literary, dramatic, musical, and neighbouring works, copyrightable works of
authorship including technical descriptions for products, user guides, illustrations, advertising
materials, computer programs, source code and object code, and all applications therefor; |
| (iv) | trademarks,
service marks, tradenames, business names and domain names and all applications therefor; |
| (v) | industrial
designs and all other industrial or intellectual property and all applications therefor;
and |
| (vi) | all
goodwill connected with the foregoing. |
| (e) | “Inventions”
shall mean any and all inventions, discoveries, developments, enhancements, improvements,
concepts, formulas, designs, processes, ideas, writings and other works, whether or not reduced
to practice, and whether or not protectable under patent, copyright, trade secret or similar
laws. |
| (f) | “Work
Product” shall mean any and all Inventions and possible Inventions relating to
the Business of the Company and which the Executive may make or conceive, alone or jointly
with others, during their involvement in any capacity with the Company, whether during or
outside their regular working hours, except those Inventions made or conceived by the Executive
entirely on their own time that do not relate to the Business of the Company and do not derive
from any equipment, supplies, facilities, Confidential Information or other information,
gained, directly or indirectly, from or through their involvement in any capacity with the
Company. |
| (a) | Property
of the Company. The Company shall exclusively own all right, title and interest in and
to the Confidential Information, whether or not created or developed by the Executive. |
| (b) | Prior
Business Confidential Information. The Executive represents and warrants to the Company
that the Executive has not brought or used, and the Executive covenants and agrees that the
Executive will not use or bring to the Company any confidential information of any kind whatsoever
of any prior party (the "Prior Business") with whom the Executive was previously
involved, whether such involvement was as an employee, director or officer of that Prior
Business, an investor in that Prior Business, a partner in that Prior Business, a consultant
to that Prior Business or other relationship to that Prior Business (the "Prior Involvement").
The Company and the Executive acknowledge and agree that the Company is not employing the
Executive to obtain confidential information relating to any Prior Involvement and the Executive
acknowledges that the Company has advised the Executive to comply with any and all legal
obligations the Executive may have to such Prior Business. The Executive covenants and agrees
to indemnify and hold the Company harmless from any and all loss, claims, damages, expenses
and costs (including legal costs on a solicitor-client basis) of any kind whatsoever that
the Company may suffer related to of any breach by the Executive of their obligations to
such Prior Business in that regard. |
| (c) | Basic
Obligation of Confidentiality. The Executive hereby acknowledges and agrees that the
Company has disclosed and will continue to disclose to the Executive, and that the Executive
has had and will continue to have access to Confidential Information. The Executive will
receive and hold all Confidential Information on the terms and conditions set out in this
Exhibit B. Except as otherwise expressly set out in this Exhibit B, the Executive will keep
strictly confidential all Confidential Information and all other information belonging to
the Company that the Executive acquires, observes or is informed of, directly or indirectly,
in connection with the Executive’s involvement, in any capacity, with the Company both
during and after the employment in any capacity with the Company. |
| (d) | Non-Disclosure.
Except with the prior written consent of the Company or as may be expressly required in the
course of performing the Services, the Executive will not at any time, either during or after
their employment in any capacity with the Company; |
| (i) | use
or copy any Confidential Information or recollections thereof for any purpose other than
the performance of the Services for the benefit of the Company and its Affiliates; |
| (ii) | publish
or disclose any Confidential Information or recollections thereof to any person other than
to employees of the Company and its Affiliates who have a need to know such Confidential
Information in the performance of their duties for the Company or its Affiliates; |
| (iii) | permit
or cause any Confidential Information to be used, copied, published, disclosed, translated
or adapted except as otherwise expressly permitted by this Agreement; or |
| (iv) | permit
or cause any Confidential Information to be stored off the premises of the Company, including
permitting or causing such Confidential Information to be stored in electronic format on
personal computers, except in accordance with written procedures of the Company, as amended
from time to time in writing. |
| (e) | Taking
Precautions. The Executive will take all reasonable precautions necessary or prudent
to prevent material in his possession or control that contains or refers to Confidential
Information from being discovered, used or copied by third parties. |
| (f) | Control
of Confidential Information and Return of Information. All physical materials produced
or prepared by the Executive containing Confidential Information, including, without limitation,
records, devices, computer files, data, notes, reports, proposals, lists, correspondence,
specifications, drawings, plans, materials, accounts, reports, financial statements, estimates
and all other materials prepared in the course of his responsibilities to or for the benefit
of the Company or its Affiliates, together with all copies thereof (in whatever medium recorded),
shall belong exclusively to the Company, and the Executive will promptly turn over to the
Company’s possession every original and copy of any and all such items in his possession
or control upon request by the Company. If the material is such that it cannot reasonably
be delivered, upon request from the Company, the Executive will provide reasonable evidence
that such materials have been destroyed, purged or erased. |
| (g) | Purpose
of Use. The Executive agrees that they will use Confidential Information only for purposes
authorized or directed by the Company. |
| (h) | Exemptions.
The obligations of confidentiality set out in this Section 2 will not apply to |
| (i) | information
required by operation of law, court order or government agency to be disclosed, provided
that: |
| (ii) | in
the event that the Executive is required to disclose such information or material, upon becoming
aware of the obligation to disclose, unless prohibited by law the Executive will provide
to the Company prompt written notice so that the Company may seek a protective order or other
appropriate remedy and/or waive compliance with the provisions of this Agreement; |
| (iii) | if
the Company agrees that the disclosure is required by law, it will promptly give the Executive
written authorization to disclose the information for the required purposes only; |
| (iv) | if
the Company promptly informs the Executive that the Company does not agree that the disclosure
is required by law, this Agreement will continue to apply, except to the extent that a Court
of competent jurisdiction orders otherwise; and |
| (v) | if
a protective order or other remedy is not obtained or if compliance with this Agreement is
waived, the Executive will furnish only that portion of the Confidential Information that
is legally required and will exercise all reasonable efforts to obtain confidential treatment
of such Confidential Information. |
| 3 | INTELLECTUAL
PROPERTY RIGHTS |
| (a) | Property
of the Company: All Inventions and Work Product will be the sole and exclusive property
of the Company. |
| (b) | Notice
of Invention. The Executive will promptly and fully inform the Company of all Work Product,
whether or not patentable, throughout the course of their involvement, in any capacity with
the Company and from which there is a reasonable basis to believe that Intellectual Property
may be derived therefrom, whether or not developed before or after execution of this Agreement.
On their ceasing to be employed by the Company for any reason whatsoever, the Executive will
immediately deliver up to the Company all Work Product. |
| (c) | Assignment
of Rights. Subject only to the exceptions set out in Attachment 1 attached to this Exhibit
B, the Executive will irrevocably assign, and does hereby irrevocably assign, to the Company
or, at the option of the Company and upon notice from the Company, to the Company’s
designee, all of their right, title and interest in and to all Work Product, including all
Intellectual Property rights therein. To the extent that the Executive retains or acquires
legal title to any such Intellectual Property rights and interests, the Executive hereby
declares and confirms that such legal title is and will be held by them only as trustee and
agent for the Company or the Company’s designee until such time as the Executive is
able to execute a binding assignment of such rights. The Executive agrees that the Company’s
rights hereunder shall attach to all Intellectual Property rights in their Work Product,
notwithstanding that it may be perfected or reduced to specific form after they have terminated
their relationship with the Company. The Executive further agrees that the Company’s
rights hereunder are worldwide rights and are not limited to Canada, but shall extend to
every country of the world. |
| (d) | Moral
Rights. Without limiting the foregoing, the Executive hereby irrevocably waives any and
all moral rights worldwide, including without limitation those arising under the Copyright
Act (Canada), as amended, or any successor legislation of similar force and effect or
similar legislation in other applicable jurisdictions or at common law that they may have
with respect to all Work Product, and agrees never to assert any moral rights which they
may have in the Work Product, including, without limitation, the right to the integrity of
the Work Product, the right to be associated with the Work Product, the right to restrain
or claim damages for any distortion, mutilation or other modification or enhancement of the
Work Product and the right to restrain the use or reproduction of the Work Product in any
context and in connection with any product, service, cause or institution, and the Executive
further confirms that the Company may use or alter any Work Product as the Company sees fits
in its absolute discretion. |
| (e) | Goodwill.
The Executive hereby agrees that all goodwill that the Executive has established or may establish
with clients, customers, suppliers, principals, shareholders, investors, collaborators, strategic
partners, licensees, contacts or prospects of the Company relating to the Business of the
Company (or of its partners, subsidiaries or affiliates), both before and after the Effective
Date, shall be and remain the property of the Company exclusively, for the Company to use,
alter, vary, adapt and exploit as the Company shall determine in its discretion. |
| (f) | Assistance.
The Executive hereby agrees to reasonably assist the Company, at the Company’s request
and expense, in: |
| (i) | making
patent applications for all Work Product, including instructions to lawyers and/or patent
agents as to the characteristics of the Work Product in sufficient detail to enable the preparation
of a suitable patent specification, to execute all formal documentation incidental to an
application for letters patent and to execute assignment documents in favour of the Company
for such applications; |
| (ii) | making
applications for all other forms of Intellectual Property registration relating to all Work
Product; |
| (iii) | prosecuting
and maintaining the patent applications and other Intellectual Property relating to all Work
Product; and |
| (iv) | registering,
maintaining and enforcing the patents and other Intellectual Property registrations relating
to all Work Product. |
| (v) | If
the Company is unable for any reason to secure the Executive’s signature with respect
to any Work Product including, without limitation, to apply for or to pursue any application
for any patents or copyright registrations covering such Work Product, then the Executive
hereby irrevocably designates and appoints the Company and its duly authorized officers and
agents as their agent and attorney-in-fact, to act for and in their behalf and stead to execute
and file any papers, oaths and to do all other lawfully permitted acts with respect to such
Work Product with the same legal force and effect as if executed by them. |
| (g) | Assistance
with Proceedings. The Executive will reasonably assist the Company, at the Company’s
request and expense, in connection with any defence to an allegation of infringement of another
person’s intellectual property rights, claim of invalidity of another person’s
intellectual property rights, opposition to, or intervention regarding, an application for
letters patent, copyright or trademark or other proceedings relating to Intellectual Property
or applications for registration thereof. |
| (h) | Commercialization.
The Executive understands that the decision whether or not to commercialize or market any
Work Product is within the Company’s sole discretion and for the Company’s sole
benefit and that no royalty or other consideration will be due or payable to him as a result
of the Company’s efforts to commercialize or market any such Work Product. |
| (i) | Prior
Business Intellectual Property. The Executive represents and warrants to the Company
that they have not brought or used, and the Executive covenants and agrees that they will
not use or bring to the Company any Intellectual Property of any kind whatsoever of any Prior
Business with whom the Executive had a Prior Involvement or any Intellectual Property directly
owned by the Executive. The Company and the Executive acknowledge and agree that the Company
is not employing the Executive to obtain Intellectual Property relating to any Prior Involvement
and the Executive acknowledges that the Company has advised the Executive to comply with
any legal obligations the Executive may have to such Prior Business. The Executive covenants
and agrees to indemnify and hold the Company harmless from any and all losses, claims, damages,
expenses, and costs (including legal costs on a solicitor-client basis) of any kind whatsoever
that the Company may suffer related to any breach by the Executive of his obligations to
such Prior Business in that regard. |
| (j) | Prior
Inventions. In order to have them excluded from this Exhibit B, the Executive has set
forth on Attachment 1 attached to this Exhibit B a complete list of all Inventions for which
a patent application has not yet been filed that they have, alone or jointly with others,
conceived, developed or reduced to practice prior to the execution of this Exhibit B to which
they have any right, title or interest, and which relate to the Business of the Company.
If such list is blank or no such list is attached, the Executive represents and warrants
that there are no such prior Inventions. |
The
Executive shall not, without the prior written consent of the Company, make or give any public announcements, press releases or statements
to the public or the press regarding any Work Product or any Confidential Information.
The
Parties will execute and deliver to each other such further instruments and assurances and do such further acts as may be required to
give effect to this Exhibit B.
The
provisions of this Exhibit B are additional to and do not amend, replace or otherwise reduce the Executive’s fiduciary obligations
at law or equity.
| 7 | TERMINATION
OF EMPLOYMENT / SURVIVAL |
| (a) | The
covenants in this Exhibit B apply regardless of which Party initiated the termination of
the Executive’s employment or the reasons for the termination of the Executive’s
employment. |
| (b) | If
the employment of the Executive is terminated for any reason by the Executive or the Company
and there is any dispute with respect to whether any obligations have been breached or to
what extent compensation or other entitlements are owing to the Executive then despite the
dispute and whether the Company is, or is later determined to be, otherwise in compliance
with the terms and conditions of the Executive’s employment, the Executive will at
all times remain bound by the post-employment obligations set out in this Exhibit B. |
| (c) | This
Exhibit B will survive the termination of employment of the Executive for any reason and
will continue in full force and effect. |
| 8 | NO
CONFLICTING OBLIGATIONS |
The
Executive hereby represents and warrants that the Executive has no agreements with or obligations to any other person with respect to
the matters covered by this Exhibit B or concerning the Confidential Information that are in conflict with anything in this Exhibit B,
except as disclosed in Attachment 1 attached to this Exhibit B.
For
the purposes of section 9(e) of the EEA, each covenant or obligation set out in this Exhibit B is a separate and distinct provision.
| 10 | INDEPENDENT
LEGAL ADVICE |
The
Executive agrees that the Executive has obtained or has had an opportunity to obtain independent legal advice in connection with this
Exhibit B, and further acknowledges that the Executive has read, understands, and agrees to be bound by all of the terms and conditions
contained herein.
Agreed: |
/s/ Netta Jagpal |
Date: 20 February 2024 |
|
|
Narinder Netta “Neeta” Jagpal |
|
|
Agreed: |
/s/ Eric A. Admas |
Date: 20 February 2024 |
|
|
Eric A. Adams |
|
|
|
INMED PHARMACEUTICALS INC. |
|
|
Attachment
1 to Exhibit B
EXCLUSIONS
FROM WORK PRODUCT
Exhibit
C – Restrictive Covenant Agreement
Dated:
20 February 2024
WHEREAS:
| A. | In
accordance with the terms of the Executive Employment Agreement between the Executive and
the Company dated 20 February 2024 (the “EEA”), the Executive has agreed
to execute this Restrictive Covenant Agreement on the terms set out herein. |
NOW
THEREFORE for good and valuable consideration, including the consideration contemplated by the EEA, the receipt and sufficiency of which
is acknowledged by the Executive, the Executive and the Company agree as follows:
The
capitalized terms have the meanings ascribed to them in the EEA, and the following terms have the following meanings:
| (a) | “Business”
or “Business of the Company” means researching, developing, commercializing,
producing and marketing novel, cannabinoid-based and other pharmaceutical therapies to treat
disease combined with innovative drug delivery systems; |
| (b) | “Capacity”
means as a principal, agent, employee, director, officer, advisor, shareholder, consultant
or contractor. |
| (c) | “Competing
Business” means any endeavor, activity or business which is competitive in any
material way with the Business of the Company worldwide; |
| (d) | “Competitive
Duties” means any duties that: |
| (i) | are
the same or similar to any of the duties the Executive performed for the Company in the 18-month
period immediately preceding the Date of Termination and relate to products and/or services
that are competitive with the Business of the Company, or |
| (ii) | involve
the management, direction or supervision of personnel performing any of the duties described
in paragraph (i) above; |
| (e) | “Contact”
means any person, firm, corporation or other entity that was a client, customer, supplier,
principal, shareholder, investor, collaborator, strategic partner, licensee, contact or prospect
of the Company (or of its partners or funders) with whom the Executive materially dealt or
otherwise became aware of during the term of the Executive’s employment in any capacity
with the Company; |
| (f) | “Restricted
Period” means the 12-month period immediately following the Date of Termination; |
| (g) | “Prohibited
Work” means any executive, management, supervisory, consultation or strategic work
for a Competing Business in circumstances where the Executive has Confidential Information,
or had been given Confidential Information, that if used or disclosed in performing such
work could be advantageous to the Competing Business in competing with the Business; and |
| (h) | “Restricted
Territory” means the United States of America and Canada and the geographic area
in any other country in which the Company had material business relationships in which the
Executive was materially involved at the time of or within 12 months of the Date of Termination. |
The
Executive acknowledges the following:
| (a) | The
Business of the Company is highly competitive; |
| (b) | The
Executive has had and will continue to have a senior executive role for the Company, has
had and will continue to have extensive access to, and has been and will continue to be entrusted
with, highly sensitive Confidential Information and has been and will continue to be involved
in and responsible for strategic, supervisory and managerial decisions for the Company; |
| (c) | The
Executive has developed and will continue to develop important relationships with key Contacts
such that the goodwill and competitiveness of the Business of the Company depend in part
on the Executive; and |
| (d) | As
a result, the Company would be vulnerable to and harmed by the Executive performing duties
and work that are competitive with or detrimental to the Company for a reasonable period
after the Date of Termination. |
| (a) | Restriction.
During the Restricted Period, the Executive shall not, without the prior written consent
of the Board acting reasonably, directly or indirectly, perform Competitive Duties or Prohibited
Work for a Competing Business in any Capacity within the Restricted Territory. |
| (b) | Exception.
Nothing in subsection (a) above shall prohibit the Executive from, during the Restricted
Period, holding, strictly for portfolio purposes and as a passive investor, no more than
five percent (5%) of the issued and outstanding shares of, or any other interest in, any
corporation or other entity which is listed on any recognized stock exchange, that is a Competing
Business. |
| 4 | NON-SOLICITATION
OF CONTACTS |
| (a) | Restriction.
During the Restricted Period the Executive shall not directly or indirectly in a manner that
is competitive with the Business of the Company: |
| (i) | participate
in any bid or tender process with respect to, or |
| (ii) | solicit
or otherwise interfere with the relationship with the Company with |
any
Contact in the Restricted Territory.
| (b) | Exception.
The restriction in paragraph (a) does not apply to solicitation through broadly circulated
media advertisements that are generic in nature. |
| 5 | NON-SOLICITATION
OF PERSONNEL |
| (a) | Restriction.
During the Restricted Period the Executive shall not directly or indirectly solicit or entice
any person who is an employee or contractor of the Company to leave employment or engagement
with the Company. |
| (b) | Exception.
The restriction in paragraph (a) does not apply to solicitation through broadly circulated
media advertisements that are generic in nature. |
| 6 | RELATIONSHIP
WITH A COMPETITIVE BUSINESS |
If
the Executive has any direct or indirect relationship with a Competitive Business any time during the Restricted Period, then the Executive
will have the duty and responsibility to promptly notify the Company of such relationship and cooperate in any investigation by the Company
as to whether the Executive is or will be in breach of any obligation in this Exhibit C. The Executive will promptly cooperate and comply
with any requests from any of the Company for information or documentation related to any such relationship with a Competitive Business.
The
Executive agrees and acknowledges that the covenants and obligations in this Exhibit C are given for good and valuable consideration,
paid or provided in exchange for agreeing to the restrictions set out in this Exhibit C and that by reason of the Executive’s unique
knowledge of and relationship with the Company and the significant competitive relationship between the Company and the Competing Businesses,
the scope of these covenants and obligations as to time, activity and geographic area, the definitions of Competing Business, Competitive
Duties, Prohibited Work, Restricted Period, and Restricted Territory are reasonable and give only such reasonable restrictions as are
minimally necessary to protect the legitimate proprietary interests of the Company. The Executive further agrees and acknowledges that
the Company may notify any employer or prospective employer of the Executive, and any other legal entity with whom the Executive has
had or is having direct or indirect dealings with, of the restrictions set out in this Exhibit C when reasonably required by the Company
to protect its legitimate business interests.
The
provisions of this Exhibit C are additional to and do not amend, replace or otherwise reduce the Executive’s fiduciary obligations
at law or equity.
| 9 | TERMINATION
OF EMPLOYMENT / SURVIVAL |
| (a) | The
covenants in this Exhibit C apply regardless of which Party initiated the termination of
the Executive’s employment or the reasons for the termination of the Executive’s
employment. |
| (b) | If
the employment of the Executive is terminated for any reason by the Executive or the Company
and there is any dispute with respect to whether any obligations have been breached or to
what extent compensation or other entitlements are owing to the Executive then despite the
dispute and whether the Company is, or is later determined to be, otherwise in compliance
with the terms and conditions of the Executive’s employment, the Executive will at
all times remain bound by the post-employment obligations set out in this Exhibit C. |
| (c) | This
Exhibit C will survive the termination of employment of the Executive for any reason and
will continue in full force and effect. |
| 10 | NO
CONFLICTING OBLIGATIONS |
The
Executive hereby represents and warrants that they have no agreements with or obligations to any other person with respect to the matters
covered by this Exhibit C.
For
the purposes of section 9(e) of the EEA, each covenant or obligation set out in this Exhibit C is a separate and distinct provision.
| 12 | INDEPENDENT
LEGAL ADVICE |
The
Executive agrees that the Executive has obtained or has had an opportunity to obtain independent legal advice in connection with this
Exhibit C, and further acknowledges that the Executive has read, understands, and agrees to be bound by all of the terms and conditions
contained herein.
Agreed: |
/s/ Netta Jagpal |
Date: 20 February 2024 |
|
|
Narinder Netta “Neeta” Jagpal |
|
|
Agreed: |
/s/ Eric A. Admas |
Date: 20 February 2024 |
|
|
Eric A. Adams |
|
|
|
INMED PHARMACEUTICALS INC. |
|
|
Exhibit
D – Release
FOR
AND IN CONSIDERATION OF the terms set out in the Executive Employment Agreement dated 20 February 2024 (the “EEA”)
and other good and valuable consideration, Narinder Netta “Neeta” Jagpal (the “Executive”) agrees
to remise, release and forever discharge of INMED PHARMACEUTICALS INC. (the “Company”), and the Company’s
associated or related entities, subsidiaries, predecessors, successors, assigns, officers, owners, operators, directors, employees, insurers
and agents and each of their associated or related entities, subsidiaries, predecessors, successors, assigns, officers, owners, operators,
directors, employees, insurers and agents and each of their respective predecessors, successors, heirs, executors, administrators, and
assigns from any and all manner of actions, causes of action, suits, debts, damages, covenants, contracts, costs, expenses, compensation,
claims and demands whatsoever, whether in law or in equity, whether known or unknown, relating to the Executive’s employment with
the Company or the cessation of that employment, and without limiting the generality of the foregoing, any claims or rights under the
Employment Standards Act (British Columbia) and the Human Rights Code (British Columbia) and any other applicable provincial
or federal legislation (to the maximum extent permitted by such legislation), any claims for severance pay or pay in lieu of notice of
termination, damages for loss of reputation, loss of position, loss of status, loss of future job opportunities, and constructive termination,
any claims arising from the manner and timing of the termination, and any claims or rights under the weekly indemnity, long term disability,
incentive and other benefit plans of the Company.
Except
for amounts to be paid or benefits and other entitlements to be provided to the Executive pursuant to the express terms of the EEA after
the date of execution of this Release, the Executive agrees and acknowledges that:
| (a) | the
Executive has received, or by virtue of the terms of the EEA will receive, all wages including,
without limiting the generality of the foregoing, overtime pay, vacation pay, general holiday
pay and pay in respect of termination of employment to which the Executive is entitled under
the Employment Standards Act as of the date of this Release; |
| (b) | the
Company has, or by virtue of the terms of the EEA will have, satisfied all obligations to
the Executive under the Employment Standards Act in relation to the Executive’s
employment and the cessation of the Executive’s employment, and there is no factual
or legal basis for any claim or entitlement against the Company under that statute; |
| (c) | the
payments to the Executive by or on behalf of the Company are not to be construed as an admission
of liability on the part of the Company, which liability is expressly denied; |
| (d) | this
Release is executed by the Executive for the purpose of making a full, final and irrevocable
settlement of any and all claims whatsoever and howsoever arising against the Company; |
| (e) | the
Executive will not make any further claim or take any proceedings whatsoever against the
Company or any other person, company or other legal entity who might claim contribution or
indemnity from the Company in respect of matters which are the subject of this Release; |
| (f) | the
facts in respect of which this Release is made may prove to be other than or different from
the facts now known or believed to be true, and the Executive expressly accepts and assumes
the risk of the facts being different, and agrees that this Release will be in all respects
enforceable and not subject to termination, rescission, or variation by discovery of any
difference in facts; |
| (g) | the
Executive will indemnify and hold harmless the Company from all liability, if any, for any
tax, penalty, interest or any other amount of any kind whatsoever arising under any one or
more of the Income Tax Act (Canada), the Employment Insurance Act (Canada),
the Canada Pension Plan Act (Canada), and any other similar statute of Canada or a
province or territory thereof, that arises in consequence of the performance of the obligations
to the Executive by or on behalf of the Company; |
| (h) | the
existence and terms of the settlement between the Executive and the Company and this Release
are confidential and the Executive will not disclose, except as required by law, either the
whole or part of such settlement or Release to anyone, but disclosure may be made to the
Executive’s legal or financial advisors and spouse, on the condition that the Executive
will ensure that those persons to whom the Executive makes disclosure maintain that confidentiality
and do not disclose the existence and terms of the settlement; |
| (i) | this
Release is voluntarily executed and the terms of the Release are contractual and not a mere
recital; and |
| (j) | the
Executive had read and understands this Release and has, prior to the execution hereof, had
the opportunity to receive independent legal advice in respect hereof. |
IN
WITNESS WHEREOF Narinder Netta “Neeta” Jagpal HAS SIGNED THIS RELEASE THIS ___ DAY OF _________________, 20__.
|
|
Narinder Netta “Neeta” Jagpal |
|
Exhibit 99.1
|
NASDAQ: INM
Suite 310-815 W. Hastings St.
Vancouver, BC, Canada V6C 1B4
Tel: +1.604.669.7207
Email: info@inmedpharma.com
www.inmedpharma.com |
InMed Pharmaceuticals
Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
Vancouver, BC –
February 9, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the
manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the appointment
of Ms. Netta Jagpal, CPA, CA as Chief Financial Officer and Corporate Secretary, effective February 20, 2024.
“We are excited
to welcome Ms. Jagpal to InMed and are fortunate to have someone of her caliber and experience join our executive leadership team,”
commented Eric A. Adams, President and Chief Executive Officer. “Netta has served in leadership positions with multiple public
and private companies and brings a wealth of experience in the biotech industry. Netta’s experience in leading all aspects of the
finance and accounting functions makes her an ideal candidate to support both InMed’s core pharmaceutical drug development business
and BayMedica’s commercial enterprise.”
Ms. Jagpal joins InMed with over 20 years of experience
in financial leadership roles, primarily in the biotech industry. Prior to InMed, Ms. Jagpal served as Vice President, Financial Reporting
& Compliance for D-Wave Systems Inc. (NYSE:QBTS) where she led a finance team through the initial public offering process. Prior to
D-Wave, Netta spent 11 years at Zymeworks Inc. (NYSE:ZYME), a leading Vancouver based clinical stage biopharmaceutical company, in various
financial roles including Senior Director, Finance & Corporate Controller. Netta has also previously held roles at Angiotech Pharmaceuticals,
Inc. (NASDAQ:ANP) and Ernst & Young. Netta is a Chartered Professional Accountant with the Institute of Chartered Accountants of British
Columbia and holds a Bachelor of Business Administration degree in Accounting and Organization Behaviour from Simon Fraser University.
In conjunction with this
appointment, Mr. Jonathan Tegge will be stepping down as Interim CFO effective February 20, 2024. The Company is grateful for the leadership
and technical expertise that Mr. Tegge contributed over the past year and looks forward to his continued involvement with InMed.
About InMed:
InMed
Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid
analogs. Together with our subsidiary, BayMedica LLC, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum
of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid
therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical
drugs. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E:
cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking
information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning
of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”,
“anticipates”, “believes”, “intends”, “potential”, “possible”, “would”
and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: statements
with respect to the appointment of a new Chief Financial Officer and relating timings; being a global leader in the manufacturing, development
and commercialization of rare cannabinoids and proprietary cannabinoid analogs; having unparalleled cannabinoid manufacturing capabilities
to serve a spectrum of consumer markets, including pharmaceutical and health and wellness.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.
v3.24.0.1
Cover
|
Feb. 08, 2024 |
Entity Addresses [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 08, 2024
|
Entity File Number |
001-39685
|
Entity Registrant Name |
INMED
PHARMACEUTICALS INC.
|
Entity Central Index Key |
0001728328
|
Entity Tax Identification Number |
98-1428279
|
Entity Incorporation, State or Country Code |
A1
|
Entity Address, Address Line One |
Suite
310 - 815 W. Hastings Street,
|
Entity Address, City or Town |
Vancouver
|
Entity Address, State or Province |
BC
|
Entity Address, Country |
CA
|
Entity Address, Postal Zip Code |
V6C
1B4
|
City Area Code |
604
|
Local Phone Number |
669-7207
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Shares, no par
value
|
Trading Symbol |
INM
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Former Address [Member] |
|
Entity Addresses [Line Items] |
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
dei_EntityAddressesLineItems |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
InMed Pharmaceuticals (NASDAQ:INM)
過去 株価チャート
から 4 2024 まで 5 2024
InMed Pharmaceuticals (NASDAQ:INM)
過去 株価チャート
から 5 2023 まで 5 2024